Antithrombotic therapy for secondary prevention of atherothrombotic events in cerebrovascular disease

Davide Capodanno, Mark Alberts, Dominick J. Angiolillo

Research output: Contribution to journalReview article

11 Citations (Scopus)

Abstract

Atherothrombosis is the common underlying process for numerous progressive manifestations of cardiovascular disease, including coronary artery disease (CAD) and cerebrovascular disease (CVD). Antiplatelet therapy is the cornerstone of pharmacological management in patients with atherothrombosis. Over the past 20 years, major advances in antiplatelet pharmacotherapy have been made, particularly for the treatment of patients with CAD. The treatment of patients with concomitant CAD and CVD is complex, owing to their increased risk of both ischaemia and bleeding. When CVD arises from large artery atherosclerosis, antithrombotic therapies are essential to prevent stroke or transient ischaemic attack (TIA). However, the use of antithrombotic medications in patients with CVD can put them at high risk of intracranial haemorrhage. As such, the risk-benefit profile of various combinations of antiplatelet agents in patients with both CAD and CVD is uncertain. This Review provides a state-of-the-art account of the available evidence on antithrombotic therapies for the secondary prevention of atherothrombotic events in patients with concomitant CAD and CVD, particularly those with a history of noncardioembolic stroke or TIA.

Original languageEnglish (US)
Pages (from-to)609-622
Number of pages14
JournalNature Reviews Cardiology
Volume13
Issue number10
DOIs
StatePublished - Oct 1 2016

Fingerprint

Cerebrovascular Disorders
Secondary Prevention
Coronary Artery Disease
Transient Ischemic Attack
Therapeutics
Stroke
Intracranial Hemorrhages
Platelet Aggregation Inhibitors
Atherosclerosis
Cardiovascular Diseases
Ischemia
Arteries
Pharmacology
Hemorrhage
Drug Therapy

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Antithrombotic therapy for secondary prevention of atherothrombotic events in cerebrovascular disease. / Capodanno, Davide; Alberts, Mark; Angiolillo, Dominick J.

In: Nature Reviews Cardiology, Vol. 13, No. 10, 01.10.2016, p. 609-622.

Research output: Contribution to journalReview article

@article{b322ec6d22ad47e8b695b855b33ca746,
title = "Antithrombotic therapy for secondary prevention of atherothrombotic events in cerebrovascular disease",
abstract = "Atherothrombosis is the common underlying process for numerous progressive manifestations of cardiovascular disease, including coronary artery disease (CAD) and cerebrovascular disease (CVD). Antiplatelet therapy is the cornerstone of pharmacological management in patients with atherothrombosis. Over the past 20 years, major advances in antiplatelet pharmacotherapy have been made, particularly for the treatment of patients with CAD. The treatment of patients with concomitant CAD and CVD is complex, owing to their increased risk of both ischaemia and bleeding. When CVD arises from large artery atherosclerosis, antithrombotic therapies are essential to prevent stroke or transient ischaemic attack (TIA). However, the use of antithrombotic medications in patients with CVD can put them at high risk of intracranial haemorrhage. As such, the risk-benefit profile of various combinations of antiplatelet agents in patients with both CAD and CVD is uncertain. This Review provides a state-of-the-art account of the available evidence on antithrombotic therapies for the secondary prevention of atherothrombotic events in patients with concomitant CAD and CVD, particularly those with a history of noncardioembolic stroke or TIA.",
author = "Davide Capodanno and Mark Alberts and Angiolillo, {Dominick J.}",
year = "2016",
month = "10",
day = "1",
doi = "10.1038/nrcardio.2016.111",
language = "English (US)",
volume = "13",
pages = "609--622",
journal = "Nature Reviews Cardiology",
issn = "1759-5002",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - Antithrombotic therapy for secondary prevention of atherothrombotic events in cerebrovascular disease

AU - Capodanno, Davide

AU - Alberts, Mark

AU - Angiolillo, Dominick J.

PY - 2016/10/1

Y1 - 2016/10/1

N2 - Atherothrombosis is the common underlying process for numerous progressive manifestations of cardiovascular disease, including coronary artery disease (CAD) and cerebrovascular disease (CVD). Antiplatelet therapy is the cornerstone of pharmacological management in patients with atherothrombosis. Over the past 20 years, major advances in antiplatelet pharmacotherapy have been made, particularly for the treatment of patients with CAD. The treatment of patients with concomitant CAD and CVD is complex, owing to their increased risk of both ischaemia and bleeding. When CVD arises from large artery atherosclerosis, antithrombotic therapies are essential to prevent stroke or transient ischaemic attack (TIA). However, the use of antithrombotic medications in patients with CVD can put them at high risk of intracranial haemorrhage. As such, the risk-benefit profile of various combinations of antiplatelet agents in patients with both CAD and CVD is uncertain. This Review provides a state-of-the-art account of the available evidence on antithrombotic therapies for the secondary prevention of atherothrombotic events in patients with concomitant CAD and CVD, particularly those with a history of noncardioembolic stroke or TIA.

AB - Atherothrombosis is the common underlying process for numerous progressive manifestations of cardiovascular disease, including coronary artery disease (CAD) and cerebrovascular disease (CVD). Antiplatelet therapy is the cornerstone of pharmacological management in patients with atherothrombosis. Over the past 20 years, major advances in antiplatelet pharmacotherapy have been made, particularly for the treatment of patients with CAD. The treatment of patients with concomitant CAD and CVD is complex, owing to their increased risk of both ischaemia and bleeding. When CVD arises from large artery atherosclerosis, antithrombotic therapies are essential to prevent stroke or transient ischaemic attack (TIA). However, the use of antithrombotic medications in patients with CVD can put them at high risk of intracranial haemorrhage. As such, the risk-benefit profile of various combinations of antiplatelet agents in patients with both CAD and CVD is uncertain. This Review provides a state-of-the-art account of the available evidence on antithrombotic therapies for the secondary prevention of atherothrombotic events in patients with concomitant CAD and CVD, particularly those with a history of noncardioembolic stroke or TIA.

UR - http://www.scopus.com/inward/record.url?scp=84982915226&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84982915226&partnerID=8YFLogxK

U2 - 10.1038/nrcardio.2016.111

DO - 10.1038/nrcardio.2016.111

M3 - Review article

C2 - 27489191

AN - SCOPUS:84982915226

VL - 13

SP - 609

EP - 622

JO - Nature Reviews Cardiology

JF - Nature Reviews Cardiology

SN - 1759-5002

IS - 10

ER -